Marinus Pharmaceuticals Says Enrollment Trends In The RAISE Trial For Intravenous Ganaxolone In Refractory Status Epilepticus Have Returned To Anticipated Levels; On Track For Topline Data In Q1 Of 2024
Portfolio Pulse from Benzinga Newsdesk
Marinus Pharmaceuticals has announced that enrollment trends in the RAISE trial for intravenous Ganaxolone in Refractory Status Epilepticus have returned to anticipated levels. The company is on track for topline data in Q1 of 2024.
September 19, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Marinus Pharmaceuticals' RAISE trial for intravenous Ganaxolone is back on track with enrollment returning to anticipated levels. Topline data is expected in Q1 2024.
The news directly pertains to Marinus Pharmaceuticals and its RAISE trial. The return to anticipated enrollment levels is a positive sign, indicating that the trial is progressing as planned. This could potentially lead to positive investor sentiment, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100